首页 > 最新文献

Pharmacoepidemiology and Drug Safety最新文献

英文 中文
Age- and Sex-Related Trends in Psychotropic Prescribing Among Youths in Denmark and the United States: 2010-2020. 丹麦和美国青少年中精神药物处方的年龄和性别相关趋势:2010-2020。
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70256
Phuong Tran, Lotte Rasmussen, Alejandro Amill-Rosario, Mette Bliddal, Susan dosReis, Rikke Wesselhoeft

Objectives: To compare age- and sex-specific trends of psychotropic prescribing between Danish and US 3-17-year-old youths.

Methods: A consecutive annual cross-sectional study of trends in psychotropic prescribing from 2010 to 2020. Data sources included the Danish National Prescription Registry data and, for the US, a 25% random sample of the IQVIA PharMetrics Plus for Academics database. Psychotropic prescribing (i.e., ADHD medications, antidepressants, and antipsychotics), measured as annual prevalence, was estimated for each therapeutic class, by age group and sex, separately by country. We used Joinpoint models to calculate the average annual percentage change (AAPC).

Results: ADHD medication prescribing decreased for 5-9 year-olds in both countries from 2010 to 2020, while prescribing among 10-17 year-olds was stable in the US and increased in Denmark, particularly among females (AAPC = 4.2% versus 1.4% among males). Antidepressant prescribing increased in older US youths, especially among 14-17 year-olds (AAPC = 6.5%), and females (AAPC = 7.2%). In Denmark, however, prescribing was low and decreased over time, especially among females (AAPC = -4.2%). Antipsychotic prescribing decreased in both countries for all age groups, with the largest decrease among males (Denmark: AAPC = -5.2% and US: AAPC = -6.1%).

Conclusion: Pediatric antipsychotic prescribing generally decreased, whereas ADHD medication and antidepressant prescribing presented opposing patterns in the two countries. ADHD medication prescribing increased among Danish females and adolescents, but was stable in the US. Antidepressant prescribing decreased in Denmark, particularly among females, which opposed the marked rise for this group in the US. Future cross-national studies should examine the rationale underpinning variation in antidepressant prescribing.

目的:比较丹麦和美国3-17岁青少年精神药物处方的年龄和性别趋势。方法:对2010年至2020年精神药物处方趋势进行连续年度横断面研究。数据来源包括丹麦国家处方注册数据和美国IQVIA PharMetrics Plus for Academics数据库中25%的随机样本。精神药物处方(即ADHD药物、抗抑郁药和抗精神病药),以年患病率衡量,按年龄组和性别分别按国家估计每个治疗类别。我们使用Joinpoint模型计算平均年百分比变化(AAPC)。结果:从2010年到2020年,两国5-9岁儿童的ADHD药物处方减少,而美国10-17岁儿童的处方保持稳定,丹麦增加,尤其是女性(AAPC = 4.2%,男性为1.4%)。抗抑郁药处方在美国老年青年中增加,特别是在14-17岁青少年(AAPC = 6.5%)和女性(AAPC = 7.2%)中。然而,在丹麦,处方量很低,并且随着时间的推移而减少,尤其是在女性中(AAPC = -4.2%)。两国所有年龄组的抗精神病药物处方均有所减少,其中男性降幅最大(丹麦:AAPC = -5.2%,美国:AAPC = -6.1%)。结论:两国儿童抗精神病药物处方普遍减少,而ADHD药物和抗抑郁药物处方呈现相反的模式。丹麦女性和青少年的ADHD药物处方增加,但在美国保持稳定。丹麦的抗抑郁药处方减少了,尤其是在女性中,这与美国这一群体的显著增加形成了鲜明对比。未来的跨国研究应该检查抗抑郁药处方差异的基本原理。
{"title":"Age- and Sex-Related Trends in Psychotropic Prescribing Among Youths in Denmark and the United States: 2010-2020.","authors":"Phuong Tran, Lotte Rasmussen, Alejandro Amill-Rosario, Mette Bliddal, Susan dosReis, Rikke Wesselhoeft","doi":"10.1002/pds.70256","DOIUrl":"10.1002/pds.70256","url":null,"abstract":"<p><strong>Objectives: </strong>To compare age- and sex-specific trends of psychotropic prescribing between Danish and US 3-17-year-old youths.</p><p><strong>Methods: </strong>A consecutive annual cross-sectional study of trends in psychotropic prescribing from 2010 to 2020. Data sources included the Danish National Prescription Registry data and, for the US, a 25% random sample of the IQVIA PharMetrics Plus for Academics database. Psychotropic prescribing (i.e., ADHD medications, antidepressants, and antipsychotics), measured as annual prevalence, was estimated for each therapeutic class, by age group and sex, separately by country. We used Joinpoint models to calculate the average annual percentage change (AAPC).</p><p><strong>Results: </strong>ADHD medication prescribing decreased for 5-9 year-olds in both countries from 2010 to 2020, while prescribing among 10-17 year-olds was stable in the US and increased in Denmark, particularly among females (AAPC = 4.2% versus 1.4% among males). Antidepressant prescribing increased in older US youths, especially among 14-17 year-olds (AAPC = 6.5%), and females (AAPC = 7.2%). In Denmark, however, prescribing was low and decreased over time, especially among females (AAPC = -4.2%). Antipsychotic prescribing decreased in both countries for all age groups, with the largest decrease among males (Denmark: AAPC = -5.2% and US: AAPC = -6.1%).</p><p><strong>Conclusion: </strong>Pediatric antipsychotic prescribing generally decreased, whereas ADHD medication and antidepressant prescribing presented opposing patterns in the two countries. ADHD medication prescribing increased among Danish females and adolescents, but was stable in the US. Antidepressant prescribing decreased in Denmark, particularly among females, which opposed the marked rise for this group in the US. Future cross-national studies should examine the rationale underpinning variation in antidepressant prescribing.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70256"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12587754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Causal Forests Versus Inverse Probability of Treatment Weighting to Adjust for Cluster-Level Confounding: A Parametric and Plasmode Simulation Study Based on US Hospital Electronic Health Record Data. 因果森林与治疗加权逆概率以调整聚类水平混杂:基于美国医院电子健康记录数据的参数化和等离子模式模拟研究
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70257
Mike Du, Stephen Johnston, Paul M Coplan, Victoria Y Strauss, Sara Khalid, Daniel Prieto-Alhambra

Background: Rapid innovation and new regulations increase the need for post-marketing surveillance of implantable devices. However, complex multi-level confounding related to patient-level and surgeon or hospital covariates hampers observational studies of risks and benefits. We conducted two simulation studies to compare the performance of Causal Forests (CF) versus Inverse Probability of Treatment Weighting (IPTW) to reduce confounding bias in the presence of strong surgeon impact on treatment allocation.

Methods: Two Monte Carlo simulation studies were carried out: (1) Parametric simulations with patients nested in clusters (ratio 10:1, 50:1, 100:1, 200:1, 500:1) and sample size n = 10 000 were conducted with patient and cluster level confounders; (2) Plasmode simulations generated from a cohort of 9981 patients admitted for pancreatectomy between 2015 and 2019 from the US PINC AT hospital research database. Different CF algorithms and IPTW were used to estimate binary treatment effects.

Results: Performance varied with the strength of cluster-level confounding. Under weak to moderate surgeon influence, CF and IPTW performed similarly. When confounding was strong (OR = 2.5), CF reduced bias compared with IPTW: in parametric simulations, relative bias averaged 11.2% for CF versus 19.9% for IPTW, with similar advantages observed in plasmode simulations.

Conclusions: CF shows promise as a method for estimating treatment effects in scenarios where cluster-level confounding strongly impacts treatment allocation. More research is needed to guide its use.

背景:快速创新和新法规增加了对植入式设备上市后监测的需求。然而,与患者水平、外科医生或医院协变量相关的复杂多层次混杂因素阻碍了对风险和获益的观察性研究。我们进行了两项模拟研究,比较因果森林(CF)和治疗加权逆概率(IPTW)的性能,以减少在外科医生对治疗分配有强烈影响的情况下的混杂偏倚。方法:进行两项蒙特卡罗模拟研究:(1)以患者为样本(比例为10:1,50:1,100:1,200:1,500:1)进行参数化模拟,样本量n = 10000,患者和集群水平混杂;(2)从2015年至2019年美国PINC AT医院研究数据库中入院的9981例胰腺切除术患者的Plasmode模拟。使用不同的CF算法和IPTW来估计二元处理效果。结果:性能随聚类水平混杂的强度而变化。在轻度至中度外科医生影响下,CF和IPTW的表现相似。当混杂较强(OR = 2.5)时,CF比IPTW减少偏倚:在参数模拟中,CF的相对偏倚平均为11.2%,而IPTW为19.9%,在等离子模模拟中也观察到类似的优势。结论:在集群水平混杂严重影响治疗分配的情况下,CF有望作为估计治疗效果的方法。需要更多的研究来指导它的使用。
{"title":"Causal Forests Versus Inverse Probability of Treatment Weighting to Adjust for Cluster-Level Confounding: A Parametric and Plasmode Simulation Study Based on US Hospital Electronic Health Record Data.","authors":"Mike Du, Stephen Johnston, Paul M Coplan, Victoria Y Strauss, Sara Khalid, Daniel Prieto-Alhambra","doi":"10.1002/pds.70257","DOIUrl":"10.1002/pds.70257","url":null,"abstract":"<p><strong>Background: </strong>Rapid innovation and new regulations increase the need for post-marketing surveillance of implantable devices. However, complex multi-level confounding related to patient-level and surgeon or hospital covariates hampers observational studies of risks and benefits. We conducted two simulation studies to compare the performance of Causal Forests (CF) versus Inverse Probability of Treatment Weighting (IPTW) to reduce confounding bias in the presence of strong surgeon impact on treatment allocation.</p><p><strong>Methods: </strong>Two Monte Carlo simulation studies were carried out: (1) Parametric simulations with patients nested in clusters (ratio 10:1, 50:1, 100:1, 200:1, 500:1) and sample size n = 10 000 were conducted with patient and cluster level confounders; (2) Plasmode simulations generated from a cohort of 9981 patients admitted for pancreatectomy between 2015 and 2019 from the US PINC AT hospital research database. Different CF algorithms and IPTW were used to estimate binary treatment effects.</p><p><strong>Results: </strong>Performance varied with the strength of cluster-level confounding. Under weak to moderate surgeon influence, CF and IPTW performed similarly. When confounding was strong (OR = 2.5), CF reduced bias compared with IPTW: in parametric simulations, relative bias averaged 11.2% for CF versus 19.9% for IPTW, with similar advantages observed in plasmode simulations.</p><p><strong>Conclusions: </strong>CF shows promise as a method for estimating treatment effects in scenarios where cluster-level confounding strongly impacts treatment allocation. More research is needed to guide its use.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70257"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12583492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perinatal Outcomes After the Use of Kampo Medicines Containing Ephedra During Pregnancy. 怀孕期间使用含麻黄的汉布药后的围产期结局。
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70251
Aoi Noda, Ryutaro Arita, Taku Obara, Minoru Ohsawa, Satoko Suzuki, Ken Haneda, Ryo Obara, Kei Morishita, Genki Shinoda, Keiko Murakami, Masatsugu Orui, Mami Ishikuro, Akiko Kikuchi, Shin Takayama, Tadashi Ishii, Shinichi Kuriyama

Purpose: Japanese traditional (Kampo) medicines containing ephedra are used to relieve symptoms of the common cold during pregnancy. The risks associated with perinatal outcomes, however, remain unclear. Thus, we evaluated the risk of adverse perinatal outcomes associated with the use of Kampo medicines containing ephedra during pregnancy using data from the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study).

Methods: Questionnaires were distributed to pregnant women who participated in the TMM BirThree Cohort Study at approximately weeks 12 and 26 of pregnancy. Adverse perinatal outcomes in women who used Kampo medicines containing ephedra or acetaminophen during pregnancy were assessed. Odds ratios (ORs) were estimated using weighted logistic regression analyses.

Results: Among 20 083 pregnant women, acetaminophen and Kampo medicines containing ephedra were used by 5.3% and 3.5% of women, respectively. The OR for caesarean section was 0.95 (95% confidence interval [CI], 0.75-1.20), for preterm birth (PTB) was0.99 (95% CI, 0.63-1.55), for low birth weight (LBW) was 1.04 (95% CI, 0.72-1.49), for small for gestational age (SGA) was 0.98 (95% CI, 0.58-1.65), and for low Apgar scores at 5 min was 0.85 (95% CI, 0.25-2.93) in the women who used Kampo medicines containing ephedra during pregnancy.

Conclusions: No statistically significant association was seen between the use of Kampo medicines containing ephedra during pregnancy and an increased risk of needing a caesarean section, PTB, LBW, SGA, or low Apgar scores. Although further research is needed, this study may assist in clinical decision-making.

用途:含有麻黄的日本传统(汉布)药物用于缓解怀孕期间的普通感冒症状。然而,与围产期结局相关的风险仍不清楚。因此,我们使用来自东北医学大库项目出生和三代队列研究(TMM BirThree队列研究)的数据,评估与妊娠期间使用含麻黄的汉布药相关的不良围产期结局风险。方法:对参加TMM BirThree队列研究的孕妇在怀孕约12周和26周时发放问卷。评估怀孕期间使用含有麻黄或对乙酰氨基酚的汉布药的妇女的不良围产期结局。使用加权逻辑回归分析估计优势比(ORs)。结果:2083例孕妇中,使用对乙酰氨基酚和含麻黄的汉布药的比例分别为5.3%和3.5%。剖宫产的OR值为0.95(95%可信区间[CI], 0.75-1.20),早产(PTB)的OR值为0.99 (95% CI, 0.63-1.55),低出生体重(LBW)的OR值为1.04 (95% CI, 0.72-1.49),小胎龄(SGA)的OR值为0.98 (95% CI, 0.58-1.65),在怀孕期间使用含麻黄的汉布药的妇女中,5分钟低Apgar评分为0.85 (95% CI, 0.25-2.93)。结论:在怀孕期间使用含有麻黄的汉布药物与需要剖腹产、PTB、LBW、SGA或低Apgar评分的风险增加之间没有统计学上的显著关联。虽然需要进一步的研究,但本研究可能有助于临床决策。
{"title":"Perinatal Outcomes After the Use of Kampo Medicines Containing Ephedra During Pregnancy.","authors":"Aoi Noda, Ryutaro Arita, Taku Obara, Minoru Ohsawa, Satoko Suzuki, Ken Haneda, Ryo Obara, Kei Morishita, Genki Shinoda, Keiko Murakami, Masatsugu Orui, Mami Ishikuro, Akiko Kikuchi, Shin Takayama, Tadashi Ishii, Shinichi Kuriyama","doi":"10.1002/pds.70251","DOIUrl":"10.1002/pds.70251","url":null,"abstract":"<p><strong>Purpose: </strong>Japanese traditional (Kampo) medicines containing ephedra are used to relieve symptoms of the common cold during pregnancy. The risks associated with perinatal outcomes, however, remain unclear. Thus, we evaluated the risk of adverse perinatal outcomes associated with the use of Kampo medicines containing ephedra during pregnancy using data from the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study).</p><p><strong>Methods: </strong>Questionnaires were distributed to pregnant women who participated in the TMM BirThree Cohort Study at approximately weeks 12 and 26 of pregnancy. Adverse perinatal outcomes in women who used Kampo medicines containing ephedra or acetaminophen during pregnancy were assessed. Odds ratios (ORs) were estimated using weighted logistic regression analyses.</p><p><strong>Results: </strong>Among 20 083 pregnant women, acetaminophen and Kampo medicines containing ephedra were used by 5.3% and 3.5% of women, respectively. The OR for caesarean section was 0.95 (95% confidence interval [CI], 0.75-1.20), for preterm birth (PTB) was0.99 (95% CI, 0.63-1.55), for low birth weight (LBW) was 1.04 (95% CI, 0.72-1.49), for small for gestational age (SGA) was 0.98 (95% CI, 0.58-1.65), and for low Apgar scores at 5 min was 0.85 (95% CI, 0.25-2.93) in the women who used Kampo medicines containing ephedra during pregnancy.</p><p><strong>Conclusions: </strong>No statistically significant association was seen between the use of Kampo medicines containing ephedra during pregnancy and an increased risk of needing a caesarean section, PTB, LBW, SGA, or low Apgar scores. Although further research is needed, this study may assist in clinical decision-making.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70251"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12583451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overlap Weights for Binary Outcomes: A Performance Assessment. 二元结果的重叠权值:一种性能评估。
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70253
Seo Young Park, Jaeil Ahn, Jae Hoon Lee, Jaewoo Kwon, Hana Lee

Background: Inverse probability weighting (IPW) is a widely used method to estimate the causal effect of treatment from observational data. However, it can be unstable when extreme propensity score (PS) values lead to very large weights. Overlap weights (OW), which emphasize subjects in areas of covariate overlap, reduce the influence of extreme PS without excluding participants. While the OW method has shown strong performance in simulations with continuous outcomes, its utility in binary outcome settings-common in health research-has not been thoroughly evaluated.

Methods: We conducted simulation studies to evaluate the performance of OW in comparison to other PS weighting methods including IPW, trimmed IPW, and matching weights, in settings with extreme PS values and a binary outcome. Using simulated datasets with varying degrees of PS overlap and treatment prevalence, we assessed covariate balance and treatment effect estimation performance. The performance of the PS weighting methods was further illustrated through an application to data from a study on pancreatic ductal adenocarcinoma.

Results: In simulation studies, IPW's performance deteriorated markedly as the overlap in the covariate distribution decreased. In contrast, OW achieved exact covariate balance and consistently showed the highest efficiency among all methods evaluated. In the application to real-world data characterized by low treatment prevalence and substantial covariate imbalance, OW also outperformed the other methods in terms of both standard error and covariate balance.

Conclusion: These findings suggest superior performance of OW in terms of covariate balance and estimation efficiency in settings with extreme PS and a binary outcome.

背景:逆概率加权(IPW)是一种广泛使用的从观测数据估计治疗因果效应的方法。然而,当极端倾向得分(PS)值导致非常大的权重时,它可能是不稳定的。重叠权重(OW)强调协变量重叠区域的受试者,在不排除参与者的情况下减少极端PS的影响。虽然OW方法在具有连续结果的模拟中表现出很强的性能,但它在健康研究中常见的二元结果设置中的效用尚未得到彻底评估。方法:我们进行了模拟研究,以评估OW与其他PS加权方法(包括IPW、修剪IPW和匹配权重)在极端PS值和二元结果设置下的性能。利用不同PS重叠程度和治疗流行程度的模拟数据集,我们评估了协变量平衡和治疗效果估计性能。通过对胰腺导管腺癌研究数据的应用,进一步说明了PS加权方法的性能。结果:在模拟研究中,随着协变量分布的重叠减少,IPW的性能明显恶化。相比之下,OW达到了精确的协变量平衡,并且在所有评估的方法中始终显示出最高的效率。在应用于治疗患病率低、协变量失衡严重的现实数据时,OW在标准误差和协变量平衡方面也优于其他方法。结论:这些发现表明,在极端PS和二元结果的情况下,OW在协变量平衡和估计效率方面表现优异。
{"title":"Overlap Weights for Binary Outcomes: A Performance Assessment.","authors":"Seo Young Park, Jaeil Ahn, Jae Hoon Lee, Jaewoo Kwon, Hana Lee","doi":"10.1002/pds.70253","DOIUrl":"https://doi.org/10.1002/pds.70253","url":null,"abstract":"<p><strong>Background: </strong>Inverse probability weighting (IPW) is a widely used method to estimate the causal effect of treatment from observational data. However, it can be unstable when extreme propensity score (PS) values lead to very large weights. Overlap weights (OW), which emphasize subjects in areas of covariate overlap, reduce the influence of extreme PS without excluding participants. While the OW method has shown strong performance in simulations with continuous outcomes, its utility in binary outcome settings-common in health research-has not been thoroughly evaluated.</p><p><strong>Methods: </strong>We conducted simulation studies to evaluate the performance of OW in comparison to other PS weighting methods including IPW, trimmed IPW, and matching weights, in settings with extreme PS values and a binary outcome. Using simulated datasets with varying degrees of PS overlap and treatment prevalence, we assessed covariate balance and treatment effect estimation performance. The performance of the PS weighting methods was further illustrated through an application to data from a study on pancreatic ductal adenocarcinoma.</p><p><strong>Results: </strong>In simulation studies, IPW's performance deteriorated markedly as the overlap in the covariate distribution decreased. In contrast, OW achieved exact covariate balance and consistently showed the highest efficiency among all methods evaluated. In the application to real-world data characterized by low treatment prevalence and substantial covariate imbalance, OW also outperformed the other methods in terms of both standard error and covariate balance.</p><p><strong>Conclusion: </strong>These findings suggest superior performance of OW in terms of covariate balance and estimation efficiency in settings with extreme PS and a binary outcome.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70253"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145409688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological Profile of Exogenous Intoxications by Self-Medication in Brazil: A Decade of Trends and the Impact of the COVID-19. 巴西自我用药外源性中毒的流行病学概况:十年趋势和COVID-19的影响
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70269
Lucas Borges Pereira, Júlia Casanova Durante, Leonardo Régis Leira Pereira, Fabiana Rossi Varallo, Maria Olívia Barboza Zanetti

Purpose: Self-medication carries the potential for significant adverse events when practiced irresponsibly. The indiscriminate use of medicines notably intensified during the COVID-19 pandemic. This study aimed to investigate the epidemiological profile of exogenous intoxications due to self-medication among Brazilians from 2014 to 2023.

Methods: This was a cross-sectional, descriptive, and exploratory study utilizing secondary data from the Brazilian Ministry of Health's Notifiable Diseases Information System. Confirmed cases of self-medication intoxication reported between 2014 and 2023 were included. Descriptive analysis, incidence and lethality rate calculations, chi-squared tests (p ≤ 0.05), and Multiple Correspondence Analysis (MCA) were performed to explore potential associations between sociodemographic and clinical variables.

Results: A total of 23 859 cases were analyzed. The study observed a predominance of adults (20-59 years), women (70.8%), and individuals self-identifying as White or Brown (mixed-race). Most cases resulted from an acute-single exposure to the medication and resolved with complete recovery without sequelae. There was a national increase in incidence, particularly in 2022 and 2023, and significant variations among Brazilian Federative Units. The MCA identified associations between advanced age and the type of exposure (repeated or chronic) and the severity of outcomes. It also revealed changes in the sociodemographic profile of self-medication intoxications during the COVID-19 pandemic.

Conclusions: These findings underscore the pandemic's impact on self-medication patterns and intoxication notifications. The study highlights the need for public policies focused on health education, appropriate medicine use, and strengthening the culture of reporting in Brazil.

目的:当不负责任地进行自我药疗时,可能会产生严重的不良事件。在2019冠状病毒病大流行期间,滥用药物的情况明显加剧。本研究旨在调查2014年至2023年巴西人因自我药疗引起的外源性中毒的流行病学概况。方法:这是一项横断面、描述性和探索性研究,利用巴西卫生部法定疾病信息系统的二手数据。包括2014年至2023年报告的自我药物中毒确诊病例。采用描述性分析、发病率和死亡率计算、卡方检验(p≤0.05)和多重对应分析(MCA)来探讨社会人口学与临床变量之间的潜在关联。结果:共分析23 859例。研究发现,主要是成年人(20-59岁)、女性(70.8%)和自认为是白人或棕色人种(混血人种)的人。大多数病例是由急性单次用药引起的,并且完全恢复,没有后遗症。在全国范围内,特别是在2022年和2023年,发病率有所上升,巴西联邦单位之间存在显著差异。MCA确定了高龄与暴露类型(重复或慢性)和结果严重程度之间的关联。它还揭示了COVID-19大流行期间自我药疗中毒的社会人口特征的变化。结论:这些发现强调了疫情对自我用药模式和中毒通报的影响。该研究强调了巴西需要制定侧重于卫生教育、适当用药和加强报告文化的公共政策。
{"title":"Epidemiological Profile of Exogenous Intoxications by Self-Medication in Brazil: A Decade of Trends and the Impact of the COVID-19.","authors":"Lucas Borges Pereira, Júlia Casanova Durante, Leonardo Régis Leira Pereira, Fabiana Rossi Varallo, Maria Olívia Barboza Zanetti","doi":"10.1002/pds.70269","DOIUrl":"10.1002/pds.70269","url":null,"abstract":"<p><strong>Purpose: </strong>Self-medication carries the potential for significant adverse events when practiced irresponsibly. The indiscriminate use of medicines notably intensified during the COVID-19 pandemic. This study aimed to investigate the epidemiological profile of exogenous intoxications due to self-medication among Brazilians from 2014 to 2023.</p><p><strong>Methods: </strong>This was a cross-sectional, descriptive, and exploratory study utilizing secondary data from the Brazilian Ministry of Health's Notifiable Diseases Information System. Confirmed cases of self-medication intoxication reported between 2014 and 2023 were included. Descriptive analysis, incidence and lethality rate calculations, chi-squared tests (p ≤ 0.05), and Multiple Correspondence Analysis (MCA) were performed to explore potential associations between sociodemographic and clinical variables.</p><p><strong>Results: </strong>A total of 23 859 cases were analyzed. The study observed a predominance of adults (20-59 years), women (70.8%), and individuals self-identifying as White or Brown (mixed-race). Most cases resulted from an acute-single exposure to the medication and resolved with complete recovery without sequelae. There was a national increase in incidence, particularly in 2022 and 2023, and significant variations among Brazilian Federative Units. The MCA identified associations between advanced age and the type of exposure (repeated or chronic) and the severity of outcomes. It also revealed changes in the sociodemographic profile of self-medication intoxications during the COVID-19 pandemic.</p><p><strong>Conclusions: </strong>These findings underscore the pandemic's impact on self-medication patterns and intoxication notifications. The study highlights the need for public policies focused on health education, appropriate medicine use, and strengthening the culture of reporting in Brazil.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70269"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12620163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using Merative MarketScan Research Databases. 利用Merative MarketScan研究数据库进行药物安全信号检测的主动比较器自控案例系列的性能。
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70250
Astrid Coste, Angel Y S Wong, Francois Haguinet, Andrew Bate, Ian J Douglas

Background: Despite testing of epidemiological methods in US Claims databases for signal detection, such data sources have not become a routine capability. The Self Controlled Case Series (SCCS) is one of the most promising methods for drug safety signal detection using Real World Data, and incorporating active comparators could potentially improve its performance by addressing confounding by indication.

Objectives: This study aims to evaluate the performance of the SCCS with and without active comparators for signal detection using US Merative MarketScan Commercial Claims and Medicare databases.

Methods: We applied the SCCS to macrolide and fluoroquinolone antibiotics, using amoxicillin and cefalexin as active comparators. In total, 7 drugs and 30 outcomes from all organ classes were selected. We developed a reference set of 104 positive controls and 58 negative controls, using a taxonomy framework to ensure the selected drug outcome pairs are theoretically well suited to the SCCS design. A two-year observation period with a 30-day risk window after each dispensing was used. Diagnostic performance was measured using sensitivity and specificity with respect to the product labels.

Results: The SCCS without active comparators achieved sensitivities of 0.73 and 0.72 and specificities of 0.68 and 0.62 in commercial and Medicare claims, respectively, for pairs with sufficient power. Active comparators increased specificity up to 0.84 and 0.86, respectively, in Commercial Claims and Medicare but decreased sensitivity to 0.45 and 0.36.

Conclusions: MarketScan databases are potentially suitable for drug safety signal detection due to their large size and information contained. Using a carefully designed reference set of drug-outcome pairs well suited to the study design, the SCCS, while imperfect, performed comparably to optimal settings identified in previously published studies. Active comparators did not enhance overall performance but showed improved specificity by better controlling confounding by indication at the cost of reduced sensitivity.

背景:尽管在美国索赔数据库中测试了流行病学方法用于信号检测,但此类数据源尚未成为常规能力。自我控制病例系列(SCCS)是使用真实世界数据进行药物安全信号检测的最有前途的方法之一,结合主动比较器可以通过解决适应症混淆问题来潜在地提高其性能。目的:本研究旨在利用US Merative MarketScan商业索赔和医疗保险数据库评估SCCS在信号检测方面的性能。方法:将SCCS应用于大环内酯类和氟喹诺酮类抗生素,以阿莫西林和头孢氨苄为活性比较物。总共从所有器官分类中选择了7种药物和30个结局。我们建立了104个阳性对照和58个阴性对照的参考集,使用分类框架确保所选药物结局对在理论上非常适合SCCS设计。2年观察期,每次配药后30天的风险窗口期。使用产品标签的敏感性和特异性来测量诊断性能。结果:无活性比较物的SCCS在商业和医疗保险索赔中,对于具有足够功率的配对,灵敏度分别为0.73和0.72,特异性分别为0.68和0.62。在商业索赔和医疗保险中,活性比较器的特异性分别增加到0.84和0.86,但敏感性降低到0.45和0.36。结论:MarketScan数据库容量大,信息量大,适合用于药物安全信号检测。SCCS使用精心设计的一组非常适合研究设计的药物结局对作为参考,虽然不完美,但其表现与先前发表的研究中确定的最佳设置相当。活性比较器没有提高总体性能,但通过降低灵敏度为代价的适应症更好地控制混杂,从而提高了特异性。
{"title":"Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using Merative MarketScan Research Databases.","authors":"Astrid Coste, Angel Y S Wong, Francois Haguinet, Andrew Bate, Ian J Douglas","doi":"10.1002/pds.70250","DOIUrl":"10.1002/pds.70250","url":null,"abstract":"<p><strong>Background: </strong>Despite testing of epidemiological methods in US Claims databases for signal detection, such data sources have not become a routine capability. The Self Controlled Case Series (SCCS) is one of the most promising methods for drug safety signal detection using Real World Data, and incorporating active comparators could potentially improve its performance by addressing confounding by indication.</p><p><strong>Objectives: </strong>This study aims to evaluate the performance of the SCCS with and without active comparators for signal detection using US Merative MarketScan Commercial Claims and Medicare databases.</p><p><strong>Methods: </strong>We applied the SCCS to macrolide and fluoroquinolone antibiotics, using amoxicillin and cefalexin as active comparators. In total, 7 drugs and 30 outcomes from all organ classes were selected. We developed a reference set of 104 positive controls and 58 negative controls, using a taxonomy framework to ensure the selected drug outcome pairs are theoretically well suited to the SCCS design. A two-year observation period with a 30-day risk window after each dispensing was used. Diagnostic performance was measured using sensitivity and specificity with respect to the product labels.</p><p><strong>Results: </strong>The SCCS without active comparators achieved sensitivities of 0.73 and 0.72 and specificities of 0.68 and 0.62 in commercial and Medicare claims, respectively, for pairs with sufficient power. Active comparators increased specificity up to 0.84 and 0.86, respectively, in Commercial Claims and Medicare but decreased sensitivity to 0.45 and 0.36.</p><p><strong>Conclusions: </strong>MarketScan databases are potentially suitable for drug safety signal detection due to their large size and information contained. Using a carefully designed reference set of drug-outcome pairs well suited to the study design, the SCCS, while imperfect, performed comparably to optimal settings identified in previously published studies. Active comparators did not enhance overall performance but showed improved specificity by better controlling confounding by indication at the cost of reduced sensitivity.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70250"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization of Oral Contraceptives and Hormone Therapy for Menopause Among Female Individuals With Migraine With Aura: A Descriptive Study. 女性先兆偏头痛患者绝经期口服避孕药和激素治疗的应用:一项描述性研究。
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70266
Liza R Gibbs, Matthew P Fox, Hugo J Aparicio, Susan Jick

Purpose: Combined oral contraceptives (COCs) are contraindicated in migraine with aura due to stroke risk, and some hormone therapy for menopause guidelines recommend caution in this population. However, this guidance is informed by sparse or older evidence reflective of higher doses than typically prescribed today. This study aimed to describe modern-day utilization of COCs and hormone therapy among female individuals with migraine with aura from 2000 to 2024.

Methods: Using United Kingdom medical record data, this study evaluated the use of COCs and progestogen-only pills (POPs) among reproductive-age individuals and hormone therapy among post-reproductive age individuals, before and after migraine with aura diagnosis. Post-diagnosis medication utilization was described relative to baseline characteristics and pre-diagnosis use of each medication, overall and longitudinally.

Results: Among 142 867 individuals of reproductive age, 84 374 (59%) used oral contraceptives on or after migraine with aura diagnosis, predominantly POPs (n = 75 823, 53% of those with any oral contraceptive) over COCs (n = 21 968, 15%). Most oral contraceptive users in the year pre-diagnosis used COCs (n = 36 909/56760, 66%). Among 46 913 individuals of post-reproductive age, 20 990 (45%) had a prescription for hormone therapy after migraine with aura diagnosis, with transdermal formulations used increasingly over calendar time.

Conclusions: Utilization of COCs declined but did not fully cease after migraine with aura diagnosis. Post-diagnosis utilization of hormone therapy for menopause was common. Given this utilization among individuals with migraine with aura, high-quality evidence quantifying the risk of stroke associated with modern-day use of these medications in this population is needed to inform patient and provider decision making.

目的:联合口服避孕药(COCs)是偏头痛先兆的禁忌症,由于中风的风险,一些更年期激素治疗指南建议谨慎使用。然而,该指南是根据稀疏的或较旧的证据提供的,这些证据反映了比今天通常规定的剂量更高的剂量。本研究旨在描述2000年至2024年女性先兆偏头痛患者COCs和激素治疗的现代使用情况。方法:利用英国的医疗记录数据,本研究评估了育龄个体COCs和孕激素单药(POPs)的使用情况,以及育龄后个体在先兆偏头痛诊断前后的激素治疗情况。总体上和纵向上描述诊断后药物使用情况,相对于基线特征和每种药物的诊断前使用情况。结果:在142867名育龄个体中,有83474人(59%)在先兆偏头痛发作时或发作后使用口服避孕药,主要是持久性有机污染物(n = 75823,占口服避孕药患者的53%)而非COCs (n = 21968,15%)。在诊断前一年,大多数口服避孕药使用者使用COCs (n = 36 909/56760, 66%)。在46 913名育龄后个体中,20 990名(45%)在先兆诊断偏头痛后服用激素治疗处方,随着时间的推移,透皮制剂的使用越来越多。结论:先兆偏头痛后COCs的使用有所下降,但并未完全停止。诊断后使用激素治疗绝经是常见的。鉴于先兆偏头痛患者的使用情况,需要高质量的证据来量化这些药物在这一人群中与现代使用相关的中风风险,以告知患者和提供者决策。
{"title":"Utilization of Oral Contraceptives and Hormone Therapy for Menopause Among Female Individuals With Migraine With Aura: A Descriptive Study.","authors":"Liza R Gibbs, Matthew P Fox, Hugo J Aparicio, Susan Jick","doi":"10.1002/pds.70266","DOIUrl":"https://doi.org/10.1002/pds.70266","url":null,"abstract":"<p><strong>Purpose: </strong>Combined oral contraceptives (COCs) are contraindicated in migraine with aura due to stroke risk, and some hormone therapy for menopause guidelines recommend caution in this population. However, this guidance is informed by sparse or older evidence reflective of higher doses than typically prescribed today. This study aimed to describe modern-day utilization of COCs and hormone therapy among female individuals with migraine with aura from 2000 to 2024.</p><p><strong>Methods: </strong>Using United Kingdom medical record data, this study evaluated the use of COCs and progestogen-only pills (POPs) among reproductive-age individuals and hormone therapy among post-reproductive age individuals, before and after migraine with aura diagnosis. Post-diagnosis medication utilization was described relative to baseline characteristics and pre-diagnosis use of each medication, overall and longitudinally.</p><p><strong>Results: </strong>Among 142 867 individuals of reproductive age, 84 374 (59%) used oral contraceptives on or after migraine with aura diagnosis, predominantly POPs (n = 75 823, 53% of those with any oral contraceptive) over COCs (n = 21 968, 15%). Most oral contraceptive users in the year pre-diagnosis used COCs (n = 36 909/56760, 66%). Among 46 913 individuals of post-reproductive age, 20 990 (45%) had a prescription for hormone therapy after migraine with aura diagnosis, with transdermal formulations used increasingly over calendar time.</p><p><strong>Conclusions: </strong>Utilization of COCs declined but did not fully cease after migraine with aura diagnosis. Post-diagnosis utilization of hormone therapy for menopause was common. Given this utilization among individuals with migraine with aura, high-quality evidence quantifying the risk of stroke associated with modern-day use of these medications in this population is needed to inform patient and provider decision making.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70266"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suitability of Japanese Medical Databases for Studies on Infant Outcomes After Maternal Drug Exposure: An Evaluation Based on Core Data Elements. 日本医学数据库对母亲药物暴露后婴儿结局研究的适用性:基于核心数据元素的评价
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70264
Shiro Hatakeyama, Takamasa Sakai, Masami Tsuchiya, Daisuke Kikuchi, Yuri Sato, Yuki Kondo, Izumi Sato, Yuko Okada, Taku Obara

Purpose: Pharmacotherapy during pregnancy should be approached with caution due to the potential risk of adverse effects, including birth defects, in the fetus. Appropriate post-marketing surveillance and perinatal pharmacoepidemiology are essential to ensure the safety of pharmacotherapy during pregnancy. However, due to limited research infrastructure in pharmacoepidemiology, collecting reliable data on drug safety in pregnant women and infants remains a challenge in Japan. Thus, we examined the suitability (fitness for purpose) of Japanese medical databases for perinatal studies to establish infrastructure in this field.

Methods: We assessed seven available databases in Japan: the DeSC database, EBM provider, Japanese Adverse Drug Event Report database, JMDC claims database, MDV analyzer, the National Database of Health Insurance Claims, and Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study). To assess the quality of databases for maternal studies, we evaluated the content of each mother-infant linkable database based on the core data elements recommended for perinatal pharmacoepidemiology.

Results: Three of the databases were found to be mother-infant linkable: the DeSC database, JMDC claims database, and the TMM BirThree Cohort Study. The coverage of core data elements in perinatal pharmacoepidemiology was 73.5% in the DeSC and JMDC claims databases and 92.9% in the TMM BirThree Cohort Study.

Conclusion: Some representative medical databases in Japan are well suited for use in perinatal pharmacoepidemiologic research on infant outcomes.

目的:怀孕期间的药物治疗应谨慎进行,因为有潜在的不良反应风险,包括胎儿的出生缺陷。适当的上市后监测和围产期药物流行病学对确保妊娠期间药物治疗的安全性至关重要。然而,由于药物流行病学研究基础设施有限,在日本收集孕妇和婴儿药物安全性的可靠数据仍然是一项挑战。因此,我们检查了围产期研究的日本医学数据库的适用性(目的适用性),以建立该领域的基础设施。方法:我们评估了日本7个可用的数据库:DeSC数据库、EBM提供商数据库、日本不良药物事件报告数据库、JMDC索赔数据库、MDV分析仪、国家健康保险索赔数据库和东北医疗兆库项目出生和三代队列研究(TMM BirThree队列研究)。为了评估孕产妇研究数据库的质量,我们基于围产期药物流行病学推荐的核心数据元素评估了每个母婴可链接数据库的内容。结果:三个数据库被发现是母婴可链接的:DeSC数据库、JMDC索赔数据库和TMM BirThree队列研究。DeSC和JMDC索赔数据库的围产期药物流行病学核心数据元素覆盖率为73.5%,TMM BirThree队列研究的覆盖率为92.9%。结论:日本一些具有代表性的医学数据库很适合用于婴儿结局的围产期药物流行病学研究。
{"title":"Suitability of Japanese Medical Databases for Studies on Infant Outcomes After Maternal Drug Exposure: An Evaluation Based on Core Data Elements.","authors":"Shiro Hatakeyama, Takamasa Sakai, Masami Tsuchiya, Daisuke Kikuchi, Yuri Sato, Yuki Kondo, Izumi Sato, Yuko Okada, Taku Obara","doi":"10.1002/pds.70264","DOIUrl":"10.1002/pds.70264","url":null,"abstract":"<p><strong>Purpose: </strong>Pharmacotherapy during pregnancy should be approached with caution due to the potential risk of adverse effects, including birth defects, in the fetus. Appropriate post-marketing surveillance and perinatal pharmacoepidemiology are essential to ensure the safety of pharmacotherapy during pregnancy. However, due to limited research infrastructure in pharmacoepidemiology, collecting reliable data on drug safety in pregnant women and infants remains a challenge in Japan. Thus, we examined the suitability (fitness for purpose) of Japanese medical databases for perinatal studies to establish infrastructure in this field.</p><p><strong>Methods: </strong>We assessed seven available databases in Japan: the DeSC database, EBM provider, Japanese Adverse Drug Event Report database, JMDC claims database, MDV analyzer, the National Database of Health Insurance Claims, and Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study). To assess the quality of databases for maternal studies, we evaluated the content of each mother-infant linkable database based on the core data elements recommended for perinatal pharmacoepidemiology.</p><p><strong>Results: </strong>Three of the databases were found to be mother-infant linkable: the DeSC database, JMDC claims database, and the TMM BirThree Cohort Study. The coverage of core data elements in perinatal pharmacoepidemiology was 73.5% in the DeSC and JMDC claims databases and 92.9% in the TMM BirThree Cohort Study.</p><p><strong>Conclusion: </strong>Some representative medical databases in Japan are well suited for use in perinatal pharmacoepidemiologic research on infant outcomes.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70264"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12611501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145506242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). 在变化的研究环境中加强药物流行病学:欧洲药物流行病学和药物警戒中心网络(ENCePP)。
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70263
Xavier Kurz, Catherine Cohet, Susana Perez-Gutthann, Shar Rao, Helga Gardarsdottir

Key changes in the pharmacoepidemiological research environment had a significant influence on the activities of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) over the last decade. These changes included the SARS-CoV-2 pandemic, the increased access to anonymized real-world data (RWD) sources, the integration of real-world evidence (RWE) into regulatory and public health decision-making, and the emergence of new technologies and methods. This paper describes how ENCePP has evolved in this changing environment to strengthen pharmacoepidemiological methods and practice in Europe and globally. It also provides future perspectives for the network. Through a collaborative approach in non-interventional research, ENCePP will collectively continue to promote excellence for RWE generation, supporting the safe and effective use of medicines.

在过去十年中,药物流行病学研究环境的重大变化对欧洲药物流行病学和药物警戒中心网络(ENCePP)的活动产生了重大影响。这些变化包括SARS-CoV-2大流行、匿名真实世界数据(RWD)来源的增加、将真实世界证据(RWE)纳入监管和公共卫生决策,以及新技术和新方法的出现。本文描述了ENCePP如何在不断变化的环境中发展,以加强欧洲和全球的药物流行病学方法和实践。它还为网络提供了未来的前景。通过非干预性研究的合作方法,ENCePP将共同继续促进RWE世代的卓越,支持药物的安全和有效使用。
{"title":"Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).","authors":"Xavier Kurz, Catherine Cohet, Susana Perez-Gutthann, Shar Rao, Helga Gardarsdottir","doi":"10.1002/pds.70263","DOIUrl":"10.1002/pds.70263","url":null,"abstract":"<p><p>Key changes in the pharmacoepidemiological research environment had a significant influence on the activities of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) over the last decade. These changes included the SARS-CoV-2 pandemic, the increased access to anonymized real-world data (RWD) sources, the integration of real-world evidence (RWE) into regulatory and public health decision-making, and the emergence of new technologies and methods. This paper describes how ENCePP has evolved in this changing environment to strengthen pharmacoepidemiological methods and practice in Europe and globally. It also provides future perspectives for the network. Through a collaborative approach in non-interventional research, ENCePP will collectively continue to promote excellence for RWE generation, supporting the safe and effective use of medicines.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70263"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12611502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145506229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the French Administrative Healthcare Database (SNDS). 使用法国行政卫生保健数据库(SNDS)进行药物安全信号检测的主动比较器自控病例系列的性能。
IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 DOI: 10.1002/pds.70224
Astrid Coste, Angel Y S Wong, François Haguinet, Andrew Bate, Ian J Douglas

Background: The self controlled case series (SCCS) is one of the most promising methods for drug safety signal detection using real world data (RWD), and incorporating active comparators could potentially improve its performance by addressing time-varying confounding by indication. The 'Système National des Données de Santé' (SNDS) is a large nationwide administrative claims database, which has not been used extensively for drug safety signal detection. While comparable in size to other RWD sources, it is unclear to what extent the performance of SCCS correlates with that in other sources.

Objectives: This study aims to evaluate the performance of the SCCS with and without active comparators for signal detection in the French administrative healthcare database SNDS.

Methods: We applied the SCCS to macrolide and fluoroquinolone antibiotics, using amoxicillin as the active comparator. Amoxicillin was chosen as an active comparator with similar indications. In total, 7 drugs and 30 outcomes from all organ classes were selected. We developed a reference set of 104 positive controls and 58 negative controls, using a taxonomy framework to ensure the selected drug outcome pairs are theoretically well suited to the SCCS design. The observation period lasted 2 years, with a 30-day risk window after each dispensing. Diagnostic performance was measured using sensitivity and specificity with respect to the product labels.

Results: The sensitivity and specificity of the SCCS without active comparator were 0.89 and 0.43, respectively, when limited to pairs with satisfactory power. Specificity increased up to 0.91 with active comparators; however, sensitivity decreased to 0.52.

Conclusions: The SNDS is a useful data source for signal detection, particularly for outcomes captured in hospitals. Using a carefully designed reference set of drug-outcome pairs well suited to the study design, the SCCS achieved satisfactory performance for signal detection in this database. In this study, the use of active comparators improved overall performance at the expense of greatly reduced sensitivity.

背景:自我控制病例序列(SCCS)是使用真实世界数据(RWD)进行药物安全信号检测最有前途的方法之一,结合主动比较器可以通过解决指征的时变混淆问题来潜在地提高其性能。SNDS是一个大型的全国性行政索赔数据库,尚未广泛用于药物安全信号检测。虽然在规模上与其他RWD来源相当,但目前尚不清楚SCCS的性能在多大程度上与其他来源的性能相关。目的:本研究旨在评估SCCS在法国行政卫生保健数据库SNDS中信号检测的性能。方法:将SCCS应用于大环内酯类抗生素和氟喹诺酮类抗生素,并以阿莫西林为活性比较物。选择阿莫西林作为具有类似适应症的活性比较药。总共从所有器官分类中选择了7种药物和30个结局。我们建立了104个阳性对照和58个阴性对照的参考集,使用分类框架确保所选药物结局对在理论上非常适合SCCS设计。观察期2年,每次给药后有30天的风险窗口期。使用产品标签的敏感性和特异性来测量诊断性能。结果:无活性比较剂的SCCS在功率满意的情况下,敏感性和特异性分别为0.89和0.43。使用活性比较器特异性增加到0.91;然而,灵敏度下降到0.52。结论:SNDS是信号检测的有用数据源,特别是在医院捕获的结果。使用精心设计的非常适合研究设计的药物结局对参考集,SCCS在该数据库中获得了令人满意的信号检测性能。在本研究中,使用有源比较器以大大降低灵敏度为代价提高了总体性能。
{"title":"Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the French Administrative Healthcare Database (SNDS).","authors":"Astrid Coste, Angel Y S Wong, François Haguinet, Andrew Bate, Ian J Douglas","doi":"10.1002/pds.70224","DOIUrl":"10.1002/pds.70224","url":null,"abstract":"<p><strong>Background: </strong>The self controlled case series (SCCS) is one of the most promising methods for drug safety signal detection using real world data (RWD), and incorporating active comparators could potentially improve its performance by addressing time-varying confounding by indication. The 'Système National des Données de Santé' (SNDS) is a large nationwide administrative claims database, which has not been used extensively for drug safety signal detection. While comparable in size to other RWD sources, it is unclear to what extent the performance of SCCS correlates with that in other sources.</p><p><strong>Objectives: </strong>This study aims to evaluate the performance of the SCCS with and without active comparators for signal detection in the French administrative healthcare database SNDS.</p><p><strong>Methods: </strong>We applied the SCCS to macrolide and fluoroquinolone antibiotics, using amoxicillin as the active comparator. Amoxicillin was chosen as an active comparator with similar indications. In total, 7 drugs and 30 outcomes from all organ classes were selected. We developed a reference set of 104 positive controls and 58 negative controls, using a taxonomy framework to ensure the selected drug outcome pairs are theoretically well suited to the SCCS design. The observation period lasted 2 years, with a 30-day risk window after each dispensing. Diagnostic performance was measured using sensitivity and specificity with respect to the product labels.</p><p><strong>Results: </strong>The sensitivity and specificity of the SCCS without active comparator were 0.89 and 0.43, respectively, when limited to pairs with satisfactory power. Specificity increased up to 0.91 with active comparators; however, sensitivity decreased to 0.52.</p><p><strong>Conclusions: </strong>The SNDS is a useful data source for signal detection, particularly for outcomes captured in hospitals. Using a carefully designed reference set of drug-outcome pairs well suited to the study design, the SCCS achieved satisfactory performance for signal detection in this database. In this study, the use of active comparators improved overall performance at the expense of greatly reduced sensitivity.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 11","pages":"e70224"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12616763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmacoepidemiology and Drug Safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1